Emulate Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 76

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $10M

  • Investors
  • 32

Emulate General Information

Description

Developer of organ-on-a-chip technology designed to predict human response with greater precision and detail than other experimental testing methods. The company's human emulation system provides a window into the inner workings of human biology and disease, offering researchers an innovative technology that conventional cell culture or animal-based experimental testing, enabling doctors to get detailed insights into the human body and its cells.

Contact Information

Formerly Known As
Emulate Living MicroDevices
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 27 Drydock Avenue
  • 5th floor
  • Boston, MA 02210
  • United States
+1 (781)
Primary Industry
Biotechnology
Other Industries
Other Devices and Supplies
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 27 Drydock Avenue
  • 5th floor
  • Boston, MA 02210
  • United States
+1 (781)

Emulate Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Emulate Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series C) 28-Oct-2025 $10M Completed Generating Revenue
11. Grant 21-May-2024 Completed Generating Revenue
10. Later Stage VC (Series F) 20-Mar-2024 Completed Generating Revenue
9. Later Stage VC (Series E) 23-Aug-2021 Completed Generating Revenue
8. Grant 31-Dec-2020 Completed Generating Revenue
7. Later Stage VC (Series D) 23-Mar-2020 Completed Generating Revenue
6. Later Stage VC (Series C) 19-Jun-2018 Completed Generating Revenue
5. Grant 20-Jun-2017 Completed Generating Revenue
4. Early Stage VC (Series B) 20-Oct-2016 $45M $57M Completed Generating Revenue
3. Early Stage VC (Series A) 11-Jul-2014 $12M $12M Completed Generating Revenue
To view Emulate’s complete valuation and funding history, request access »

Emulate Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series F-1
Series F-3
Series F-2
Series E-2
Series E-1
Series D
Series C
Series B 18,000,000 $0.000100 6% $25 $25 1x $6.3 59.48%
Series A 18,000,000 $0.000100 6% $10 $10 1x $3.07 48.84%
To view Emulate’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Emulate Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of organ-on-a-chip technology designed to predict human response with greater precision and detail than other
Biotechnology
Boston, MA
76 As of 2026

Cambridge, United Kingdom
 

New Orleans, LA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Emulate Competitors (8)

One of Emulate’s 8 competitors is Stemnovate, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Stemnovate Venture Capital-Backed Cambridge, United Kingdom
28bio Venture Capital-Backed New Orleans, LA
MIMETAS Venture Capital-Backed Oegstgeest, Netherlands
Ncardia Venture Capital-Backed Leiden, Netherlands
CN-Bio Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 8 competitors. Get the full list »

Emulate Patents

Emulate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240082795-A1 Dispensing machine Pending 08-Sep-2022
AU-2020388676-A1 Antibody producing microfluidic devices Active 21-Nov-2019
AU-2020388676-B2 Antibody producing microfluidic devices Inactive 21-Nov-2019
CA-3158045-A1 Antibody producing microfluidic devices Pending 21-Nov-2019
GB-202208044-D0 Antibody producing microfluidic devices Active 21-Nov-2019 C07K16/00
To view Emulate’s complete patent history, request access »

Emulate Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Emulate Investors (32)

Investor Name Investor Type Holding Investor Since Participating Rounds
Lush. Corporation
Qiming Venture Partners Venture Capital Minority
United States Department of War Government
Alumni Ventures Venture Capital Minority
Alwyn Capital Venture Capital Minority
You’re viewing 5 of 32 investors. Get the full list »

Emulate FAQs

  • When was Emulate founded?

    Emulate was founded in 2013.

  • Where is Emulate headquartered?

    Emulate is headquartered in Boston, MA.

  • What is the size of Emulate?

    Emulate has 76 total employees.

  • What industry is Emulate in?

    Emulate’s primary industry is Biotechnology.

  • Is Emulate a private or public company?

    Emulate is a Private company.

  • What is Emulate’s current revenue?

    The current revenue for Emulate is .

  • How much funding has Emulate raised over time?

    Emulate has raised $278M.

  • Who are Emulate’s investors?

    Lush., Qiming Venture Partners, United States Department of War, Alumni Ventures, and Alwyn Capital are 5 of 32 investors who have invested in Emulate.

  • Who are Emulate’s competitors?

    Stemnovate, 28bio, MIMETAS, Ncardia, and CN-Bio are some of the 8 competitors of Emulate.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process